Fibroblast growth factor 5 is a protein that in humans is encoded by the FGF5gene.
The majority of FGF family members are glycosaminoglycan binding proteins which possess broad mitogenic and cell survival activities, and are involved in a variety of biological processes, including embryonic development, cell growth, morphogenesis, tissue repair, tumor growth and invasion. FGF proteins interact with a family of specific tyrosine kinase receptors, a process often regulated by proteoglycans or extracellular binding protein cofactors. A number of intracellular signalling cascades are known to be activated after FGF-FGFR interaction including PI3K-AKT, PLCγ, RAS-MAPK and STAT pathways.
FGF5 is a 268 amino acid, 29.1 kDa protein, which also naturally occurs as a 123 amino acid isoform splice variant (FGF5s) ,. FGF5 is produced in the outer root sheath of the hair follicle as well as perifollicular macrophages, with maximum expression occurring in the late anagen phase of the hair cycle,. The receptor for FGF5, FGFR1, is largely expressed in the dermal papilla cells of the hair follicle.,. The alternatively spliced isoform FGF5s, has been identified as an antagonist of FGF5 in a number of studies.,,
Research comparing different breeds of dogs has demonstrated FGF5 as a major contributing factor in coat length.
The only described function of FGF5 in adults is in the regulation of the hair cycle. FGF5 performs a critical role in the hair cycle, where it acts as the key signalling molecule in initiating the transition from the anagen (growth) phase to the catagen (regression) phase.,, Evidence of this activity was initially gathered via targeted disruption of the homolog of the FGF5 gene in mice, which resulted in a phenotype with abnormally long hair.
In numerous genetic studies of long haired phenotypes of animals it has been shown that small changes in the FGF5 gene can disrupt its expression, leading to an increase in the length of the anagen phase of the hair cycle, resulting in phenotypes with extremely long hair. This has been demonstrated in many species, including cats  dogs  mice, rabbits, donkeys, sheep and goats, where it is often referred to as the angora mutation. Recently, CRISPR modification of goats to artificially knock out the FGF5 gene, was shown to result in higher wool yield, without any fertility or other negative effects on the goats.
It has been hypothesised that, in an alternate type of mutation, positive selection for increased expression of the FGF5 protein was one of the contributing factors in the evolutionary loss of hair in cetaceans as they transitioned from the terrestrial to the aquatic environment.
FGF5 also affects the hair cycle in humans. Individuals with mutations in FGF5 exhibit familial trichomegaly, a condition that involves a significant increase in the portion of anagen phase hair as well as extremely long eyelashes. . FGF5 has also been identified as a potentially important factor in androgenetic alopecia. In 2017, a large genome wide association study of men with early onset androgenetic alopecia identified polymorphisms in FGF5 as having a strong association with male pattern hair loss.
Blocking FGF5 in the human scalp extends the hair cycle, resulting in less hair fall, faster hair growth rate and increased hair growth.,In vitro methods using engineered cell lines and FGFR1 expressing dermal papilla cells have identified a number of naturally derived botanical isolates including Sanguisorba officnalis and single molecule members of the monoterpenoid as inhibitors (blockers) of FGF5. Clinical studies have shown that topical application of formulations containing these natural extracts and molecules are beneficial in men and women experiencing hair loss.,
↑ 2.02.1Suzuki S, Kato T, Takimoto H, Masui S, Oshima H, Ozawa K, Suzuki S, Imamura T (December 1998). "Localization of rat FGF-5 protein in skin macrophage-like cells and FGF-5S protein in hair follicle: possible involvement of two Fgf-5 gene products in hair growth cycle regulation". The Journal of Investigative Dermatology. 111 (6): 963–72. doi:10.1046/j.1523-1747.1998.00427.x. PMID9856803.
↑ 8.08.18.2Hébert JM, Rosenquist T, Götz J, Martin GR (September 1994). "FGF5 as a regulator of the hair growth cycle: evidence from targeted and spontaneous mutations". Cell. 78 (6): 1017–25. PMID7923352.
↑Dierks C, Mömke S, Philipp U, Distl O (August 2013). "Allelic heterogeneity of FGF5 mutations causes the long-hair phenotype in dogs". Animal Genetics. 44 (4): 425–31. doi:10.1111/age.12010. PMID23384345.
↑Li CX, Jiang MS, Chen SY, Lai SJ (July 2008). "[Correlation analysis between single nucleotide polymorphism of FGF5 gene and wool yield in rabbits]". Yi Chuan = Hereditas. 30 (7): 893–9. PMID18779133.
↑ 19.019.119.2Maeda T, Yamamoto T, Isikawa Y, et al. (2007). "Sanguisorba Officinalis Root Extract Has FGF-5 Inhibitory Activity and Reduces Hair Loss by Causing Prolongation of the Anagen Period". Nishinihon J. Dermatology. 69 (1): 81–86. doi:10.2336/nishinihonhifu.69.81.
Li K, Stewart DJ, Ward HJ (April 1999). "Technology evaluation: gene therapy (FGF-5), Vical". Current Opinion in Molecular Therapeutics. 1 (2): 260–5. PMID11715949.
Werner S, Roth WK, Bates B, Goldfarb M, Hofschneider PH (November 1991). "Fibroblast growth factor 5 proto-oncogene is expressed in normal human fibroblasts and induced by serum growth factors". Oncogene. 6 (11): 2137–44. PMID1658709.
Hébert JM, Rosenquist T, Götz J, Martin GR (September 1994). "FGF5 as a regulator of the hair growth cycle: evidence from targeted and spontaneous mutations". Cell. 78 (6): 1017–25. doi:10.1016/0092-8674(94)90276-3. PMID7923352.
Clements DA, Wang JK, Dionne CA, Goldfarb M (May 1993). "Activation of fibroblast growth factor (FGF) receptors by recombinant human FGF-5". Oncogene. 8 (5): 1311–6. PMID8386828.
Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, Gao G, Goldfarb M (June 1996). "Receptor specificity of the fibroblast growth factor family". The Journal of Biological Chemistry. 271 (25): 15292–7. doi:10.1074/jbc.271.25.15292. PMID8663044.
Kitaoka T, Morse LS, Schneeberger S, Ishigooka H, Hjelmeland LM (April 1997). "Expression of FGF5 in choroidal neovascular membranes associated with ARMD". Current Eye Research. 16 (4): 396–9. doi:10.1076/ceyr.16.4.396.10685. PMID9134330.
Schneeberger SA, Hjelmeland LM, Tucker RP, Morse LS (October 1997). "Vascular endothelial growth factor and fibroblast growth factor 5 are colocalized in vascular and avascular epiretinal membranes". American Journal of Ophthalmology. 124 (4): 447–54. doi:10.1016/s0002-9394(14)70861-x. PMID9323936.
Kornmann M, Ishiwata T, Beger HG, Korc M (September 1997). "Fibroblast growth factor-5 stimulates mitogenic signaling and is overexpressed in human pancreatic cancer: evidence for autocrine and paracrine actions". Oncogene. 15 (12): 1417–24. doi:10.1038/sj.onc.1201307. PMID9333017.
Ozawa K, Suzuki S, Asada M, Tomooka Y, Li AJ, Yoneda A, Komi A, Imamura T (October 1998). "An alternatively spliced fibroblast growth factor (FGF)-5 mRNA is abundant in brain and translates into a partial agonist/antagonist for FGF-5 neurotrophic activity". The Journal of Biological Chemistry. 273 (44): 29262–71. doi:10.1074/jbc.273.44.29262. PMID9786939.
de Vries CJ, van Achterberg TA, Horrevoets AJ, ten Cate JW, Pannekoek H (August 2000). "Differential display identification of 40 genes with altered expression in activated human smooth muscle cells. Local expression in atherosclerotic lesions of smags, smooth muscle activation-specific genes". The Journal of Biological Chemistry. 275 (31): 23939–47. doi:10.1074/jbc.M910099199. PMID10823842.
Hanada K, Perry-Lalley DM, Ohnmacht GA, Bettinotti MP, Yang JC (July 2001). "Identification of fibroblast growth factor-5 as an overexpressed antigen in multiple human adenocarcinomas". Cancer Research. 61 (14): 5511–6. PMID11454700.
Kornmann M, Lopez ME, Beger HG, Korc M (2002). "Expression of the IIIc variant of FGF receptor-1 confers mitogenic responsiveness to heparin and FGF-5 in TAKA-1 pancreatic ductal cells". International Journal of Pancreatology. 29 (2): 85–92. doi:10.1385/IJGC:29:2:085. PMID11876253.
Sieuwerts AM, Martens JW, Dorssers LC, Klijn JG, Foekens JA (April 2002). "Differential effects of fibroblast growth factors on expression of genes of the plasminogen activator and insulin-like growth factor systems by human breast fibroblasts". Thrombosis and Haemostasis. 87 (4): 674–83. PMID12008951.